EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Harnessing chimeric antigen receptor macrophages against solid tumors

Mengru Wang, Zhen Qin, Xiu-Wu Bian, Yu Shi iD

Cancer Communications · 2025-11 · 45 (11) · 1344-1366

DOI: 10.1002/cac2.70053 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Communications, online erschienen am 17.08.2025. Verfasst von Mengru Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), the Key Laborato…. Hauptthemen laut MEDLINE: Neoplasms, Receptors, Chimeric Antigen, Macrophages, Immunotherapy, Adoptive. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Chongqing Municipality, Chongqing Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrophages are prevalent in multiple tumors and exhibit diverse and potent functional activities. Therapeutic reprogramming of macrophage phenotypes represents a promising strategy for cancer immunotherapy. Engineering chimeric antigen receptors (CARs) to endow macrophages with anti‐tumor capacities demonstrated encouraging efficacy, particularly in enhancing tumor‐targeted phagocytosis. Furthermore, CAR macrophages (CAR‐Ms) orchestrate adaptive immunity through secreting pro‐inflammatory cytokines and presenting tumor antigens, thereby activating cytotoxic T lymphocyte responses. These multifaceted properties establish CAR‐Ms as potent immunotherapeutic agents against therapy‐refractory solid malignancies. Herein, we delineate the design principles, recent research advances, and rational combination strategies of CAR‐Ms, with particular emphasis on emerging clinical evidence from ongoing CAR‐M trials. We also explore potential applications of CAR‐Ms in non‐tumorous diseases and forecast future trends based on CAR‐T therapy evolution. CAR‐M development, combined with emerging technologies, will generate new perspectives for advancing cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsReceptors, Chimeric AntigenMacrophagesImmunotherapy, AdoptiveHumansAnimalsAntigens, Neoplasm

Stichwörter der Autor:innen

chimeric antigen receptorimmunotherapymacrophagesolid tumors

Substanzen

Receptors, Chimeric AntigenAntigens, Neoplasm

Autor:innen und Institutionen

  • Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), the Key Laboratory of Tumor Immunopathology, the Ministry of Education of China, Chong…
  • Yu-Yue Pathology Scientific Research Center and Jinfeng Laboratory, Chongqing, P. R. China.

ORCID-Profile: Yu Shi

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Chongqing Municipality
  • Chongqing Municipal Health Commission
  • National Natural Science Foundation of China

Zitieren

APA

Wang, M., Qin, Z., Bian, X. W., & Shi, Y. (2025). Harnessing chimeric antigen receptor macrophages against solid tumors. Cancer Communications, 45(11), 1344-1366. https://doi.org/10.1002/cac2.70053

Vancouver

Wang M, Qin Z, Bian XW, Shi Y. Harnessing chimeric antigen receptor macrophages against solid tumors. Cancer Communications. 2025;45(11):1344-1366. doi:10.1002/cac2.70053

BibTeX
@article{Wang2025,
  author = {Wang, Mengru and Qin, Zhen and Bian, Xiu-Wu and Shi, Yu},
  title = {Harnessing chimeric antigen receptor macrophages against solid tumors},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {11},
  pages = {1344--1366},
  doi = {10.1002/cac2.70053}
}
Kostenlos starten →